AR116121A1 - Métodos de tratamiento del cáncer - Google Patents

Métodos de tratamiento del cáncer

Info

Publication number
AR116121A1
AR116121A1 ARP190102528A ARP190102528A AR116121A1 AR 116121 A1 AR116121 A1 AR 116121A1 AR P190102528 A ARP190102528 A AR P190102528A AR P190102528 A ARP190102528 A AR P190102528A AR 116121 A1 AR116121 A1 AR 116121A1
Authority
AR
Argentina
Prior art keywords
subject
cancer treatment
treatment methods
therapy
therapeutically effective
Prior art date
Application number
ARP190102528A
Other languages
English (en)
Inventor
Martin Huber
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of AR116121A1 publication Critical patent/AR116121A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un método de tratamiento de un cáncer en un sujeto, comprendiendo el método medir un nivel de expresión de PD-L1 en una muestra obtenida del sujeto; y administrar al sujeto basándose en el nivel de expresión de PD-L1: una dosis terapéuticamente eficaz de un inhibidor de poli (ADP-ribosa) polimerasa (PARP); y una dosis terapéuticamente eficaz de una terapia anti-proteína 1 de muerte programada (PD-1), en donde el sujeto no ha recibido previamente quimioterapia sistémica o ninguna terapia anti-PD-1 previa.
ARP190102528A 2018-09-04 2019-09-04 Métodos de tratamiento del cáncer AR116121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726826P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
AR116121A1 true AR116121A1 (es) 2021-03-31

Family

ID=69411494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102528A AR116121A1 (es) 2018-09-04 2019-09-04 Métodos de tratamiento del cáncer

Country Status (6)

Country Link
US (1) US20210346497A1 (es)
CN (1) CN112805003A (es)
AR (1) AR116121A1 (es)
TW (1) TW202024638A (es)
UY (1) UY38360A (es)
WO (1) WO2020051142A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021209357A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
AU2021268579A1 (en) * 2020-05-04 2022-12-01 Merck Sharp & Dohme Corp. Methods of treating cancer using a combination of a PD-1 antagonist, a chemoradiation therapy and a parp inhibitor
EP4213844A1 (en) * 2020-09-17 2023-07-26 Mirati Therapeutics, Inc. Combination therapies
KR20230163467A (ko) * 2021-03-26 2023-11-30 임팩트 테라퓨틱스 (상하이), 인코포레이티드 Parp 억제제의 경구 캡슐 및 이의 제조 방법
KR20220149268A (ko) * 2021-04-30 2022-11-08 주식회사 온코크로스 트리사이클로 유도체 화합물을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
CN114507286B (zh) * 2022-04-18 2022-07-05 苏州百道医疗科技有限公司 一种抗pd-l1重组兔单克隆抗体及其应用
WO2024081276A1 (en) * 2022-10-12 2024-04-18 Merck Sharp & Dohme Llc Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
BRPI0906020A2 (pt) 2008-01-08 2015-06-30 Merck Sharp & Dohme Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento
AR095363A1 (es) 2013-03-15 2015-10-14 Genentech Inc Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
DK2992017T3 (da) * 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) * 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
BR112018070361A2 (pt) * 2016-04-07 2019-01-29 Chemocentryx Inc redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
BR112019008859A2 (pt) 2016-11-01 2019-07-09 Anaptysbio Inc anticorpos direcionados contra a morte programada 1 (pd-1)
US20190284280A1 (en) 2016-11-01 2019-09-19 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN110382545A (zh) * 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
AU2019215450A1 (en) * 2018-02-05 2020-08-27 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods

Also Published As

Publication number Publication date
US20210346497A1 (en) 2021-11-11
WO2020051142A9 (en) 2020-05-28
UY38360A (es) 2020-03-31
TW202024638A (zh) 2020-07-01
CN112805003A (zh) 2021-05-14
WO2020051142A2 (en) 2020-03-12
WO2020051142A3 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
AR116121A1 (es) Métodos de tratamiento del cáncer
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
CL2020002945A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA202190630A1 (ru) Способы комбинированной терапии
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
MX2022008868A (es) Tratamiento del cancer con tg02.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
WO2018102687A3 (en) Combination therapy for treating cancer
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2019013862A (es) Terapia de combinacion.
WO2020092792A3 (en) Method of enhancing immune-based therapy
MX2019012660A (es) Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.
UY38352A (es) Inhibidores de integrina alfavbeta6